Production of two new blood pressure medicines in the country

Author :

Naraghi's Charity

Date: :

March 16, 2024

Specialists at a pharmaceutical company have developed two new drugs to treat high blood pressure, a condition that affects approximately 32 million Iranians to varying degrees.

The CEO of Actoverco pharmaceutical group, Reza Karimi Mostofi, reported that the specialists of his group have successfully provided the blood pressure medication Telmyc-H to patients in Iran. Telmyc-H is the first medication of its kind in Iran, containing telmisartan/hydrochlorothiazide. This medication comes in the form of coated tablets in two strengths: 80/12.5 and 80/25 mg. It is commonly used to treat high blood pressure.

He stated that approximately 32 million people in Iran suffer from high blood pressure, which is one of the leading causes of cardiovascular diseases, including heart attacks, strokes, and fatalities resulting from these conditions.Cardiovascular accidents tend to occur more frequently in the early morning hours when the balance of certain hormones in the body is disrupted. Telmisartan/hydrochlorothiazide Actoverco medicine has several benefits, including constant monitoring of blood pressure, especially during sleep at night and in the early morning, which helps in maintaining a healthy blood pressure level.

Mostofi stated that taking this medication can regulate blood pressure for 24 hours and minimize side effects.

He mentioned that the company has introduced another new medicine named Irbesal (Irbesartan) at the Salamat Bonyan exhibition of science-based products in the field of food, medicine, and medical equipment. Irbesal is available in the form of coated and lined tablets of 300mg.

Actoverco’s CEO stated that this drug is used to treat high blood pressure and diabetic nephropathy.

He pointed out that high blood pressure, which unfortunately is quite prevalent in the country, is one of the leading causes of cardiovascular and kidney diseases. He affirmed that high blood pressure complications in diabetic patients, with uncontrolled high blood sugar, can cause damage to the kidney vessels and cells. This damage to cells will eventually lead to kidney failure.In addition to controlling blood pressure, Irbesartan can be effective in preventing diabetic nephropathy, which is the excretion of protein from the kidneys.

The CEO of Actoverco Pharmaceuticals has stated that their company produces almost 400 different pharmaceutical products across 15 therapeutic areas. These products range from general disease treatments to high-risk oncology, hormonal, and biological drugs. The pharmaceutical complex is also involved in producing raw materials and supplements. To support the development of knowledge-based activities in the healthcare field, the Actotech accelerator has been launched. Mostofi stated that the knowledge-based complex became operational in 2020. The complex was inaugurated by the president’s scientific and technological deputy and the secretary of the biotechnology development staff. Currently, it is an advanced research and development complex that fulfills the requirements of a science and technology park. It supports the commercialization of innovative ideas across various fields, such as biotechnology drugs, vaccines, new drug formulations, personalized medicine, smart health, diagnostic kits, food quality control, as well as the field of raw materials, and factory production line equipment.

Related News

Neurostyle Launch Event

July 17, 2024

Helping to Treat Neuropathic Pain and Anemia with an Iranian Supplement

July 9, 2024

Actoverco launches diabetes drug “Trytis”

May 12, 2024

“International Labour Day”

May 1, 2024

Actoverco host a Futsal tournament!

April 29, 2024

Bright future for pharmaceutical industry in Iran!

April 24, 2024